全文获取类型
收费全文 | 390篇 |
免费 | 29篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 8篇 |
妇产科学 | 12篇 |
基础医学 | 64篇 |
口腔科学 | 14篇 |
临床医学 | 31篇 |
内科学 | 75篇 |
皮肤病学 | 2篇 |
神经病学 | 43篇 |
特种医学 | 16篇 |
外科学 | 35篇 |
综合类 | 2篇 |
预防医学 | 40篇 |
眼科学 | 3篇 |
药学 | 37篇 |
肿瘤学 | 35篇 |
出版年
2023年 | 6篇 |
2022年 | 8篇 |
2021年 | 16篇 |
2020年 | 8篇 |
2019年 | 17篇 |
2018年 | 12篇 |
2017年 | 9篇 |
2016年 | 16篇 |
2015年 | 15篇 |
2014年 | 20篇 |
2013年 | 31篇 |
2012年 | 35篇 |
2011年 | 35篇 |
2010年 | 27篇 |
2009年 | 17篇 |
2008年 | 14篇 |
2007年 | 19篇 |
2006年 | 18篇 |
2005年 | 17篇 |
2004年 | 16篇 |
2003年 | 16篇 |
2002年 | 7篇 |
2001年 | 6篇 |
2000年 | 4篇 |
1999年 | 7篇 |
1998年 | 3篇 |
1997年 | 1篇 |
1996年 | 1篇 |
1995年 | 2篇 |
1993年 | 3篇 |
1992年 | 5篇 |
1990年 | 2篇 |
1988年 | 1篇 |
1987年 | 3篇 |
1986年 | 1篇 |
1985年 | 1篇 |
1983年 | 1篇 |
1982年 | 1篇 |
排序方式: 共有421条查询结果,搜索用时 15 毫秒
61.
62.
Pellegrino Musto Monika Engelhardt Jo Caers Niccolo Bolli Martin Kaiser Niels van de Donk Evangelos Terpos Annemiek Broijl Carlos Fernndez de Larrea Francesca Gay Hartmut Goldschmidt Roman Hajek Annette Juul Vangsted Elena Zamagni Sonja Zweegman Michele Cavo Meletios Dimopoulos Hermann Einsele Heinz Ludwig Giovanni Barosi Mario Boccadoro Maria-Victoria Mateos Pieter Sonneveld Jesus San Miguel 《Haematologica》2021,106(11):2799
According to the updated International Myeloma Working Group criteria, smoldering multiple myeloma (SMM) is an asymptomatic plasma cell disorder characterized by an M-component >3 g/dL, bone marrow plasma cell infiltration >10% and <60%, and absence of any myeloma-defining event. Active multiple myeloma is preceded by SMM, with a median time to progression of approximately 5 years. Cases of SMM range from the extremes of “monoclonal gammopathy of undetermined significance-like”, in which patients never progress during their lifetimes, to “early multiple myeloma”, in which transformation into symptomatic disease, based on genomic evolution, may be rapid and devastating. Such a “split personality” makes the prognosis and management of individual patients challenging, particularly with regard to the identification and possible early treatment of high-risk SMM. Outside of clinical trials, the conventional approach to SMM generally remains close observation until progression to active multiple myeloma. However, two prospective, randomized trials have recently demonstrated a significant clinical benefit in terms of time to progression, and of overall survival in one of the two studies, for some patients with higher-risk SMM treated with lenalidomide ± dexamethasone, raising the question of whether such an approach should be considered a new standard of care. In this paper, experts from the European Myeloma Network describe current biological and clinical knowledge on SMM, focusing on novel insights into its molecular pathogenesis, new prognostic scoring systems proposed to identify SMM patients at higher risk of early transformation, and updated results of completed or ongoing clinical trials. Finally, some practical recommendations for the real-life management of these patients, based on Delphi consensus methodology, are provided. 相似文献
63.
64.
65.
66.
Myra E. van Linde Cyrillo G. Brahm Philip C. de Witt Hamer Jaap C. Reijneveld Anna M. E. Bruynzeel W. Peter Vandertop Peter M. van de Ven Michiel Wagemakers Hiske L. van der Weide Roelien H. Enting Annemiek M. E. Walenkamp Henk M. W. Verheul 《Journal of neuro-oncology》2017,133(1):183-192
According to the recently updated World Health Organization (WHO) classification (2016), grade II–III astrocytomas are divided into IDH-wildtype and IDH-mutant groups, the latter being significantly less aggressive in terms of both progression-free and total survival. We identified a small cohort of WHO grade II–III astrocytomas that harbored the IDH1 R132H mutation, as confirmed by both immunohistochemistry and molecular sequence analysis, which nonetheless had unexpectedly rapid recurrence and subsequent progression to glioblastoma. Among these four cases, the mean time to recurrence as glioblastoma was only 16 months and the mean total survival among the three patients who have died during the follow-up was only 31 months. We hypothesized that these tumors had other, unfavorable genetic or epigenetic alterations that negated the favorable effect of the IDH mutation. We applied genome-wide profiling with a methylation array (Illumina Infinium Human Methylation 450k) to screen for genetic and epigenetic alterations in these tumors. As expected, the methylation profiles of all four tumors were found to match most closely with IDH-mutant astrocytomas. Compared with a control group of four indolent, age-similar WHO grade II–III astrocytomas, the tumors showed markedly increased levels of overall copy number changes, but no consistent specific genetic alterations were seen across all of the tumors. While most IDH-mutant WHO grade II–III astrocytomas are relatively indolent, a subset may rapidly recur and progress to glioblastoma. The precise underlying cause of the increased aggressiveness in these gliomas remains unknown, although it may be associated with increased genomic instability. 相似文献
67.
Siobhan Conroy Michiel Wagemakers Annemiek M. E. Walenkamp Frank A. E. Kruyt Wilfred F. A. den Dunnen 《Journal of neuro-oncology》2017,131(1):11-20
Glioblastoma (GBM) is a highly vascularized and aggressive type of primary brain tumor in adults with dismal survival. Molecular subtypes of GBM have been identified that are related to clinical outcome and response to therapy. Although the mesenchymal type has been ascribed higher angiogenic activity, extensive characterization of the vascular component in GBM subtypes has not been performed. Therefore, we aimed to investigate the differential vascular status and angiogenic signaling levels in molecular subtypes. GBM tissue samples representing proneural IDH1 mutant, classical-like and mesenchymal-like subtypes were analyzed by morphometry for the number of vessels, vessel size and vessel maturity. Also the expression levels of factors from multiple angiogenic signaling pathways were determined. We found that necrotic and hypoxic areas were relatively larger in mesenchymal-like tumors and these tumors also had larger vessels. However, the number of vessels, basement membrane deposition and pericyte coverage did not vary between the subtypes. Regarding signaling patterns the majority of factors were expressed at similar levels in the subtypes, and only ANGPT2, MMP2, TIMP1, VEGFA and MMP9/TIMP2 were higher expressed in GBMs of the classical-like subtype. In conclusion, although morphological differences were observed between the subtypes, the angiogenic signaling status of GBM subtypes seemed to be rather similar. These results challenge the concept of mesenchymal GBMs being more angiogenic than other subclasses. 相似文献
68.
69.
70.
Siddesh V. Hartimath Urszula M. Domanska Annemiek M.E. Walenkamp Erik F.J. de Vries 《Nuclear medicine and biology》2013,40(4):507-517
PurposeCXCR4 plays an important role in HIV infection, tumor progression, neurogenesis, and inflammation. In-vivo imaging of CXCR4 could provide more insight in the role of this receptor in health and disease. The aim of this study was to investigate [99mTc]O2-AMD3100 as a potential SPECT tracer for imaging of CXCR4.MethodAMD3100 was labelled with [99mTc]pertechnetate. A cysteine challenge assay was performed to test the tracer stability. Heterologous and homologous receptor binding assay and internalization assay were performed in CXCR4 expressing Jurkat-T cells. Ex vivo biodistribution was studied in healthy mice at 30, 60, and 120 min after tracer injection. Tumor uptake of the tracer was determined by microSPECT imaging in nude mice xenografted with human PC-3 prostate tumor. Specificity of tracer uptake was determined by blocking studies using an excess of unlabelled AMD3100.ResultsAMD3100 was labelled with technetium-99 m with a radiochemical yield of > 98%. The tracer was stable in PBS and mouse plasma for at least 6 h at 37 °C. Heterologous and homologous binding assays with AMD3100 showed IC50 values of 240 ± 10 μM, and 92 ± 5 μM for [125I]SDF-1α and [99mTc]O2-AMD3100 respectively, with negligible receptor internalisation. The tracer showed high uptake in liver, lungs, spleen, thymus, intestine and bone. Blocking dose of AMD3100.8HCl (20 mg/kg) decreased the uptake in these organs (p < 0.05). [99mTc]O2-AMD3100 showed specific tumor accumulation in mice bearing PC-3 xenografts model. Time activity curves (TAC) in AMD3100 pre-treated animals tracer showed 1.7 times less tumor uptake as compared to control animals (p < 0.05).Conclusion[99mTc]O2-AMD3100 is readily labelled, is stable in plasma and displays a favourable binding affinity for the CXCR4 receptors. [99mTc O2-AMD3100 shows specific binding in organs with high CXCR4 expression and in CXCR4 positive tumors. These results justify further evaluation of this radiopharmaceutical as a potential biomarker for the non-invasive imaging of CXCR4 receptors. 相似文献